Mediwound (NASDAQ:MDWD) Stock Rating Upgraded by Zacks Investment Research

Mediwound (NASDAQ:MDWD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, Zacks.com reports. The firm currently has a $2.25 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 11.39% from the stock’s current price.

According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “

Separately, Oppenheimer assumed coverage on Mediwound in a report on Monday, May 18th. They issued a “buy” rating and a $7.00 target price for the company.

NASDAQ:MDWD traded up $0.02 during trading hours on Thursday, reaching $2.02. 60,026 shares of the company traded hands, compared to its average volume of 99,523. The business’s 50-day moving average price is $1.84 and its two-hundred day moving average price is $2.56. The stock has a market capitalization of $54.41 million, a P/E ratio of 8.42 and a beta of 1.42. Mediwound has a 1 year low of $1.44 and a 1 year high of $4.65. The company has a current ratio of 3.43, a quick ratio of 3.28 and a debt-to-equity ratio of 0.13.

Mediwound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, May 20th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.05. The business had revenue of $4.44 million during the quarter, compared to analysts’ expectations of $4.25 million. Mediwound had a negative return on equity of 71.14% and a net margin of 18.46%. As a group, equities analysts anticipate that Mediwound will post -0.37 EPS for the current year.

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its holdings in shares of Mediwound by 42.0% in the 4th quarter. Renaissance Technologies LLC now owns 407,408 shares of the biopharmaceutical company’s stock worth $1,263,000 after purchasing an additional 120,508 shares in the last quarter. Sargent Investment Group LLC grew its holdings in shares of Mediwound by 27.4% in the fourth quarter. Sargent Investment Group LLC now owns 60,500 shares of the biopharmaceutical company’s stock worth $188,000 after acquiring an additional 13,000 shares during the period. UBS Group AG grew its holdings in shares of Mediwound by 203.3% in the fourth quarter. UBS Group AG now owns 9,566 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 6,412 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Mediwound by 55.8% in the fourth quarter. Acadian Asset Management LLC now owns 55,027 shares of the biopharmaceutical company’s stock worth $170,000 after acquiring an additional 19,709 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Mediwound by 547.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,968 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 7,583 shares during the period. 23.93% of the stock is owned by institutional investors and hedge funds.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Article: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.